News
Ex-Wrexham captain Ben Tozer has opened up about breaking down during a pre-match warm-up after his father's sudden death in ...
Manji was sentenced to three years in prison last summer after admitting to defrauding Inuit organizations of more than $158,000 for her twin daughters' education. Manji had claimed she adopted her ...
In “Sick and Dirty,” author Michael Koresky takes a clear-eyed look at golden age Hollywood’s stealth queerness on screen.
Justin Tucker, one of the best kickers in NFL history, suspended for 10 weeks after 16 women said he was sexually ...
The Democrat will be the first woman and one of fewer than 20 Minnesotans accorded the honor. She will lie in state with her ...
Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with hemophilia A or B with inhibitors.
20h
Asianet Newsable on MSNPfizer’s Hemophilia Drug Meets Goals In Late-Stage Trial In Patients With Certain AntibodiesDuring the study, 48 people living with hemophilia were treated with Hympavzi and observed to have a 93% reduction in ...
Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...
Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, ...
Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.
Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...
Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results